Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community

The AVID-CC trial, funded through the Covid-19 Therapeutics Accelerator, will investigate whether adalimumab (two doses being evaluated) is effective in the treatment of adults in community care settings. Treatment will be delivered by Hospital at Home teams around the UK.

Source:

British Medical Journal